Announced details
Drug discovery, target molecule discovery and pharmaceutical development
The service has been adopted by multiple major pharmaceutical companies and has built up a track record. Number of companies and engagements: Not disclosed.
The companies entered into an agreement on target molecule discovery. FRONTEO will be responsible for extracting target molecule candidates and developing hypotheses regarding their mechanisms of action, while Astellas Pharma Inc. will validate the candidates. Capital and personnel relationships: Not disclosed.
Head office: Chuo-ku, Tokyo; Representative Director, President and CEO: Okamura Naoki (岡村直樹). Other company details: Not disclosed.
Patents have been obtained in Japan, Europe, the United States and South Korea. Individual patent numbers, registration dates and expiration dates: Not disclosed.
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Drug Discovery AI Factory（DDAIF）, KIBIT |
| Counterparty | Astellas Pharma Inc. |
| Counterparty overview | Head office: Chuo-ku, Tokyo; Representative Director, President and CEO: Okamura Naoki (岡村直樹). Other company details: Not disclosed. |
| Relationship with the Company | The companies entered into an agreement on target molecule discovery. FRONTEO will be responsible for extracting target molecule candidates and developing hypotheses regarding their mechanisms of action, while Astellas Pharma Inc. will validate the candidates. Capital and personnel relationships: Not disclosed. |
| Contract Date | 16 April 2026 |
| Applicable area | Drug discovery, target molecule discovery and pharmaceutical development |
| Registration number and expiry date | Patents have been obtained in Japan, Europe, the United States and South Korea. Individual patent numbers, registration dates and expiration dates: Not disclosed. |
| Usage history | The service has been adopted by multiple major pharmaceutical companies and has built up a track record. Number of companies and engagements: Not disclosed. |
Items this document does not state (10)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To combine FRONTEO's AI-based drug discovery support service with Astellas Pharma Inc.'s disease and drug discovery expertise and advanced technologies, with the aim of creating innovative medicines at an early stage.